Bavarian Nordic A/S
Denmark · DK0015998017 · reports in DKK · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +9.2% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 11% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 86% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in DKK.
DKK 6.2B
revenue
29%
operating margin
DKK 1.4B
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | DKK 3.2B | DKK 7.1B | DKK 5.7B | DKK 6.2B |
| Operating profit | −DKK 71M | DKK 1.5B | DKK 940M | DKK 1.8B |
| Earnings per share | −DKK 4.90 | DKK 19.20 | DKK 12.60 | DKK 17.60 |
| Cash from operations | DKK 220M | DKK 1.1B | DKK 1.9B | DKK 2.7B |
| Capital spending | DKK 361M | DKK 143M | DKK 83M | DKK 205M |
| Cash | DKK 575M | DKK 1.5B | DKK 1.6B | DKK 1.7B |
| Total assets | DKK 12.4B | DKK 14.4B | DKK 14.4B | DKK 15.0B |
| Equity | DKK 7.1B | DKK 10.3B | DKK 11.4B | DKK 12.9B |
What they do
In the company's own words, from the annual report.
we aspire to expand our reach and impact through the supply of life-saving vaccines that address unmet medical needs for the greater good of the global society.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.